• A disposal aligned with Novasep’s core strategy
• An opportunity for Novasep’s chromatography equipment division to accelerate its growth by joining an established leader in the sector
Novasep, a leading supplier of services and technologies for the life sciences industry, and Sartorius Stedim Biotech, a subgroup of the life science company Sartorius, have signed an agreement regarding the proposed sale of Novasep’s chromatography equipment division.
This proposed transaction covers operations located on different Novasep sites employing approximately 100 people, the majority of whom work at the Pompey site in eastern France and some in the USA, China and India.
Novasep’s chromatography equipment division comprises resin-based batch and intensified chromatography systems, and primarily focuses on high-pressure, multi-use applications for smaller molecules, such as oligonucleotides, peptides and insulin. Since 2018, Novasep and Sartorius have been collaborating in the joint development of an optimized system for a membrane-based, low-pressure chromatography that processes larger molecules more productively and that will be launched soon.
This announcement is aligned with Novasep’s Rise-2 strategy, which is focused on prioritizing its core business. The proposed transaction is a major step for the development of the equipment business worldwide, based on the long-term expertise of Novasep’s employees and Sartorius’ strong position on this market segment. It is subject to works council consultation and the approval of all relevant regulatory bodies.
“This deal marks one of the first steps in our Rise-2 strategic program to focus the group towards our core business”, said Dr. Michel Spagnol, President & CEO of Novasep. “We are delighted to strengthen our relationship with the Sartorius team and believe it will be a great opportunity for the chromatography equipment business to fully deliver its potential and accelerate its growth under this new ownership.”
“I am pleased that we will intensify our successful collaboration with the Novasep team, soon to be under the Sartorius roof,” said Dr. René Fáber, Head of the Sartorius Bioprocess Solutions Division and Executive Board member. “The Novasep portfolio will perfectly complement our existing chromatography offering and allow us to provide customers with more options for their manufacturing processes. Efficient DSP has remained a challenge in our industry for years, and Sartorius is committed to helping accelerate and simplify this crucial step so that new drugs can be manufactured much more efficiently.”
Novasep is a global provider of cost effective and sustainable manufacturing solutions for life sciences molecules. Novasep’s unique offering includes process development services, purification equipment and turnkey processes, contract manufacturing and complex active molecule services for pharmaceutical, biopharmaceutical, fine chemical, food and functional ingredients as well as fermentation and chemical commodities industries. https://www.novasep.com
About Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2019, the company employed approx. 6,200 people, and earned sales revenue of 1,440.6 million euros.
Laure Saloin & Brice Roquet
Communication Project Managers
+33 (0)7 77 94 37 52 / +33 (0)7 77 94 37 55
Sartorius Stedim Biotech contact:
Head of Corporate Communications and Investor Relations